What is artesunate, including its active component, mechanism of action, approved and off‑label indications, dosage forms and dosing regimens, safety profile, pharmacokinetics, resistance mechanisms, clinical considerations, drug interactions, and contraindications?

Artesunate: Comprehensive Clinical Overview

What is Artesunate?

Artesunate is a water-soluble, semi-synthetic derivative of artemisinin (extracted from Artemisia annua) that serves as the first-line treatment for severe malaria worldwide, with FDA approval granted in May 2020 and European Medicines Agency authorization in November 2021 1.

Active Component and Mechanism of Action

The active component is dihydroartemisinin (DHA), the primary metabolite responsible for antimalarial activity 2, 3. Artesunate is rapidly hydrolyzed to DHA within minutes of administration 4.

Mechanism of Action:

• The unique endoperoxide bridge in the molecular structure generates reactive oxygen species (ROS) when exposed to iron-rich environments
• This leads to rapid parasite killing through oxidative damage to parasite proteins and membranes
• Provides the fastest parasite clearance of any antimalarial agent 2, 4
• Additional mechanisms include cell cycle modulation, apoptosis induction, and ferroptosis activation 5, 6

Approved Disease Indications

Primary Indications

Severe/Complicated Malaria (All Plasmodium Species):

• First-line treatment for severe malaria caused by any Plasmodium species 1
• Includes cerebral malaria, shock, pulmonary edema, acute respiratory distress syndrome, severe anemia, acidosis, hypoglycemia, renal failure, and hyperparasitemia
• Demonstrated 35% reduction in mortality compared to quinine in the SEAQUAMAT trial 1, 4

Uncomplicated P. falciparum Malaria:

• Used as part of artemisinin-based combination therapies (ACTs) 1
• Registered for uncomplicated P. falciparum in combination formulations

Off-Label Use

Malaria-Related:

• Uncomplicated P. vivax malaria (off-label in combination therapy) 1
• P. ovale, P. malariae, and P. knowlesi infections 1

Non-Malaria Indications (Investigational):

• Metastatic uveal melanoma (case reports showing temporary response) 7
• Acute myeloid leukemia (anti-tumor activity demonstrated) 6
• Metabolic-associated steatohepatitis (MASH) - showing anti-inflammatory effects 5, 8
• Various cancers including gastric, hepatocellular, and colorectal carcinoma 5

Dosage Forms

Available formulations include:

• Intravenous (IV) - 110 mg vials 1
• Intramuscular (IM) 3, 9
• Oral tablets 2, 3
• Rectal suppositories 2, 3

Dosing Regimens

Standard Therapeutic Dosing for Severe Malaria

Initial Treatment (IV/IM):

• 2.4 mg/kg at 0,12, and 24 hours (three doses in first 24 hours) 1
• Then 2.4 mg/kg once daily for up to 7 days if unable to take oral medication or parasitemia >1%
• Switch to oral ACT once patient can tolerate oral intake AND parasitemia <1% 1

Critical Point: Complete a full course of oral ACT after IV artesunate to prevent recrudescence 1

Uncomplicated Malaria (Oral ACT Combinations)

Dihydroartemisinin-Piperaquine (DHA-PPQ):

• 36-75 kg: 3 tablets daily for 3 days

• 75 kg: 4 tablets daily for 3 days

• Must be taken fasting 1

Artemether-Lumefantrine (AL):

• 35 kg: 4 tablets at 0,8,24,36,48, and 60 hours (24 tablets total over 72 hours)

• Must be taken with fatty meal or drink 1

Minimum Safe and Maximum Tolerable Doses

Standard dosing of 2.4 mg/kg IV/IM is both safe and effective 1. The pharmacokinetic studies demonstrate:

• IV artesunate clearance: 2-3 L/kg/hr
• Volume of distribution: 0.1-0.3 L/kg
• Half-life: <15 minutes for artesunate, 30-60 minutes for DHA 3

No specific maximum tolerable dose is established in guidelines, but standard dosing should not be exceeded without compelling clinical indication. Monotherapy requires 5-7 days minimum to prevent recrudescence 2.

Alternative Dosing Regimens

For Pregnant Women (2nd and 3rd Trimester):

• Same dosing as non-pregnant adults: 2.4 mg/kg IV at 0,12,24 hours 1
• Artemether-lumefantrine can be used in all trimesters per WHO/CDC 1

Renal Impairment:

• No dose adjustment specified in guidelines for artesunate itself
• If continuing quinine >48 hours with renal failure, reduce quinine dose by one-third 1

Food Effect

Oral Formulations:

• Dihydroartemisinin-piperaquine: Must be taken FASTING 1
• Artemether-lumefantrine: Must be taken WITH fatty meal or drink to enhance absorption 1

Parenteral formulations: No food effect (IV/IM administration)

Side Effects and Safety Profile

Common Adverse Events

Oral ACTs:

• Headache, vertigo, digestive disorders 1
• QTc interval prolongation (particularly with piperaquine) 1
• Generally well-tolerated with minimal side effects 2, 10

IV Artesunate:

• Haemoglobinuria 1
• Post-artesunate delayed hemolysis (PADH) - see below

Serious Adverse Events

Post-Artesunate Delayed Hemolysis (PADH):

• Occurs in approximately 15% of treated patients 10
• Develops 7-30 days after treatment initiation 10
• Requires weekly monitoring of hemoglobin, haptoglobin, and LDH at days 7,14,21, and 28 1
• Blood transfusion needed in 50% of PADH cases 10
• No deaths or permanent sequelae reported 10

Critical Safety Note: In retrospective studies of 624 travelers treated with artesunate, 23 deaths occurred (4% mortality), but no deaths were attributed to artesunate toxicity 10.

Toxicity Risk Factors

Contraindications:

• Known hypersensitivity to artemisinin derivatives
• First trimester of pregnancy (use only if benefit outweighs risk; safe in 2nd/3rd trimester) 1

Use with Caution:

• Patients at risk of QTc prolongation (when using ACT combinations) 1
• Concomitant medications that prolong QTc interval 1
• G6PD deficiency (not a contraindication for artesunate, but relevant for combination with primaquine) 1

Pharmacokinetics (ADME)

Absorption

• IV: Immediate systemic availability
• IM: Almost complete bioavailability of DHA (>86%) 3, 9
• Oral: High bioavailability of DHA (>80%) 3
• Rectal: Similar to oral with delayed absorption 3

Distribution

• Artesunate: Volume of distribution 0.1-0.3 L/kg 3
• DHA: Volume of distribution 0.5-1.0 L/kg 3
• Rapid tissue penetration

Metabolism

• Extremely rapid hydrolysis to active metabolite dihydroartemisinin (DHA) 3, 4
• Conversion occurs within minutes of administration
• DHA responsible for majority of antimalarial effect 9

Elimination

• Artesunate half-life: <15 minutes (IV), 20-45 minutes (oral) 3
• DHA half-life: 30-60 minutes (IV), 0.5-1.5 hours (oral) 3
• Artesunate clearance: 2-3 L/kg/hr 3
• DHA clearance: 0.5-1.5 L/kg/hr 3

Pharmacokinetic Alterations:

• Pregnancy may alter kinetics (requires further investigation) 3
• Acute malaria infection may affect drug handling 3

Targeted Pathways and Genes

Antimalarial Mechanisms:

• ROS generation via endoperoxide bridge interaction with iron
• Oxidative damage to parasite proteins and membranes 4

Anti-tumor/Anti-inflammatory Pathways:

• ROS/Bim pathway activation (apoptosis) 6
• TFRC/Fe2+ pathway (iron homeostasis, differentiation) 6
• PPAR-α transcription factor regulation (lipid metabolism) 8
• Ferroptosis activation 5
• Cell cycle modulation and proliferation inhibition 5

Resistance Mechanisms

Critical Concern: Established resistance to ACT regimens exists in the Greater Mekong sub-region 1. Emerging resistance is a growing concern globally.

Resistance Prevention Strategy:

• Never use artesunate as monotherapy (except initial treatment of severe malaria before switching to ACT) 2
• Always combine with longer-acting partner drug (mefloquine, lumefantrine, piperaquine) 2
• Use regimens providing 90-100% radical cure rates 2
• Restrict use to areas of multidrug resistance when possible 2

Molecular Mechanisms:

• Delayed parasite clearance associated with mutations in kelch13 gene (K13)
• No specific resistance pattern to artesunate alone has been clinically confirmed to date 2

Critical Clinical Considerations

Monitoring Requirements

During Treatment:

• Severe malaria: Parasitemia every 12 hours until <1%, then every 24 hours until negative 1
• Uncomplicated malaria: Parasitemia on day 3 (expect 75% reduction) and day 7 (expect negative) 1
• Continuous ICU monitoring for severe cases (cardiovascular, pulmonary, renal, metabolic parameters) 1

Post-Treatment:

• Mandatory PADH surveillance: Hemoglobin, haptoglobin, LDH at days 7,14,21, and 28 1
• For oral ACT after IV artesunate: PADH monitoring at days 7 and 14 1

Clinical Pitfalls to Avoid

1. Do NOT use artesunate monotherapy for uncomplicated malaria - leads to high recrudescence rates 2
2. Do NOT forget to complete full ACT course after IV artesunate for severe malaria 1
3. Do NOT miss PADH monitoring - occurs in 15% of patients and may require transfusion 10
4. Do NOT use in first trimester pregnancy unless absolutely necessary 1
5. Do NOT combine DHA-piperaquine with food - must be taken fasting 1
6. Do NOT forget fatty meal with artemether-lumefantrine - required for absorption 1

Special Populations

Pregnancy:

• Safe in 2nd and 3rd trimester 1
• First-line for severe malaria in 2nd/3rd trimester 1
• Artemether-lumefantrine approved for all trimesters by WHO/CDC 1

Children:

• Same weight-based dosing as adults
• Well-tolerated 2

Travelers vs. Semi-immune:

• Hyperparasitemia threshold differs: >5% for naïve travelers, >10% for semi-immune 1

Drug Interactions

Minimal Clinically Significant Interactions:

• Does NOT alter pharmacokinetics of:

  • Atovaquone/proguanil 3
  • Chlorproguanil/dapsone 3
  • Sulfadoxine/pyrimethamine 3

• Not affected by:

  • Mefloquine 3
  • Pyronaridine 3

QTc Prolongation Risk:

• Avoid combining DHA-piperaquine or artemether-lumefantrine with other QTc-prolonging medications 1
• Avoid in patients with baseline QTc prolongation risk 1

No significant CYP450 interactions reported in clinical studies 3

Contraindications

Absolute:

• Documented hypersensitivity to artemisinin derivatives or artesunate
• First trimester pregnancy (relative - use only if benefit clearly outweighs risk)

Relative (Use with Caution):

• Baseline QTc prolongation (for ACT combinations)
• Concomitant QTc-prolonging medications (for ACT combinations)
• Severe hepatic dysfunction (theoretical concern, not absolute contraindication)

Note: The FDA label references 11 provided appear to be for ampicillin/sulbactam, not artesunate, and are therefore not applicable to this answer.